Axitinib

Axitinib Reactions 1704, p58 - 2 Jun 2018 Hypertension: case report In a report of 43 patients, one patient [age and sex not stated] was described, who developed hypertension during treatment with axitinib for advanced renal cell carcinoma [dosage and route not stated]. The patient, who had advanced renal cell carcinoma, started receiving treatment with axitinib. Subsequently, the patient developed grade 3 hypertension [duration of treatment to reaction onset not stated]. The dose of axitinib was neither escalated nor reduced [outcome not stated]. Author comment: "We have assessed the efficacy and general tolerability of axitinib in a real world setting and audited our local dose escalation/reduction practice" "1 had a grade 3 hypertension" Parkar R, et al. Axitinib: An audit of dose adjustments, tolerability and efficacy in advanced renal cell carcinoma. Annals of Oncology 29 (Suppl. 3): iii30-iii31 (plus poster) abstr. 135P, Mar 2018. Available from: URL: https://doi.org/10.1093/ annonc/mdy047.082 [abstract] - United Kingdom 803323162 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Axitinib

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/axitinib-OKwNEHrwgU
Publisher
Springer International Publishing
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46701-x
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p58 - 2 Jun 2018 Hypertension: case report In a report of 43 patients, one patient [age and sex not stated] was described, who developed hypertension during treatment with axitinib for advanced renal cell carcinoma [dosage and route not stated]. The patient, who had advanced renal cell carcinoma, started receiving treatment with axitinib. Subsequently, the patient developed grade 3 hypertension [duration of treatment to reaction onset not stated]. The dose of axitinib was neither escalated nor reduced [outcome not stated]. Author comment: "We have assessed the efficacy and general tolerability of axitinib in a real world setting and audited our local dose escalation/reduction practice" "1 had a grade 3 hypertension" Parkar R, et al. Axitinib: An audit of dose adjustments, tolerability and efficacy in advanced renal cell carcinoma. Annals of Oncology 29 (Suppl. 3): iii30-iii31 (plus poster) abstr. 135P, Mar 2018. Available from: URL: https://doi.org/10.1093/ annonc/mdy047.082 [abstract] - United Kingdom 803323162 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off